| Literature DB >> 24965383 |
Thiago Botelho Azeredo, Vera Lucia Luiza1, Maria Auxiliadora Oliveira, Isabel Cristina Martins Emmerick, Maryam Bigdeli.
Abstract
BACKGROUND: This study aims to rank policy concerns and policy-related research issues in order to identify policy and research gaps on access to medicines (ATM) in low- and middle-income countries in Latin America and the Caribbean (LAC), as perceived by policy makers, researchers, NGO and international organization representatives, as part of a global prioritization exercise.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24965383 PMCID: PMC4079916 DOI: 10.1186/1478-4505-12-31
Source DB: PubMed Journal: Health Res Policy Syst ISSN: 1478-4505
Policy/research items generated by the regional meeting in Cambodia according to the World Health Organization framework for access to medicines and Health System Level
| 1a) Information asymmetry (user knowledge level; communication and language barriers – as for ethnic minorities) | 2a) High out-of-pocket payment | 3a) Geographical accessibility: physical barriers; distance to facilities; remoteness (combination of physical barriers and infrastructure weakness) | 4a) Community financing arrangements | |
| 2c) Community participation in medicine delivery arrangements | ||||
| 4b) Role of government subsidies at community level | ||||
| 1b) Health seeking behavior, preference for private care, preference for secondary level of care (bypass primary health care), self-medication | ||||
| 4c) Focal models of subside | ||||
| 3e) Traditional medicine (e.g., unclear distinction between allopathy and non-allopathy) | ||||
| 1c) Beliefs about illness and treatment (traditional practices; demand for injections and branded medicines; prescribers and dispensers perception of quality of drugs) | ||||
| 1d) Impact of advertisements on medicines; incentives (or lack of, leading to private or dual practice); medicines becoming a source in financing for health services | 2d) Medicine price variation according to geographical location (e.g., urban/rural differences, higher prices in remote areas); price differential between public and private | 3b) Distribution systems and supply chains | 4d) Health provider payment methods | |
| 4e) Health insurance coverage and models | ||||
| 3c) Pharmaceutical services at local level | ||||
| 1e) Staff capacity for rational prescription and use of medicines; training curriculum | 3d) Informal markets – substandard quality and counterfeit medicines | |||
| 3f) Staff and technical capacity: for supply management; with managerial, interpersonal, and information technology (IT) skills; with local language skills | ||||
| 1f) Clinical treatment guidelines, and essential medicines list: development; incentives for implementation; operational mechanisms; standardization (including between private and public sectors) | ||||
| 3g) Responsiveness to patient needs; differential responsiveness between public and private | ||||
| 1g) Incentives for rational use of medicines and for implementation of generic policy | ||||
| 3j) Availability of medicines (especially in public sector) | ||||
| 1h) Staff deployment | 2b) Opportunity costs | 3h) Public-private mix: reliance on private sector delivery; public-private partnerships and their role in access to medicines | 4f) Government budgets for medicines | |
| 2e) Medicine price information system | 4g) Reimbursement policies | |||
| 1i) Pharmacovigilance, information on adverse drug reaction, and other problems related to medicines | 2f) Impact of prices on access | |||
| 4h) Cost containment policies | ||||
| 3i) Central procurement policies vs. decentralization | ||||
| 2g) Policy and regulation for medicines price | ||||
| 3k) Quality assurance | ||||
| 2h) Incentives for implementation of generic policy | ||||
| 3l) Coordination between health policies and medicines policies; referral policy/referral system | ||||
| 1j) Medicine information system (not only price information)/competing with medicines advertisement | ||||
| 3m) Monitoring and evaluation systems; funding for monitoring and evaluation | ||||
| 1k) Intersectoral initiatives (e.g., rational use of medicines in schools – role of Ministry of Education) | 2i) Patents and intellectual property issues | 3n) Governance and governing: law and regulation enforcement; transparency and accountability | 4i) Donor funding; harmonization and alignment; verticalized donor support | |
| 2j) Finance policies: taxes, autonomy, privatization; exemption systems | ||||
| 4j) Patents and intellectual property issues | ||||
| 3o) Regional integration and economic cooperation (example: UNASUL, MERCOSUL) | ||||
| 4k) Finance policies: taxes, autonomy, privatization | ||||
| 2k) Trade and economic goals (impact of health sector policies outside the health sector) | ||||
| 4l) Trade and economic goals (impact of health sector policies outside the health sector) | ||||
| 3p) Promotion of research and development – new drugs/neglected diseases. | ||||
| 2l) Budget allocation to health | 4m) Budget allocation to health | |||
| 2m) Medicine production | 3q) Medicine production | |||
*Item codes reflect the order in which they appeared in the questionnaire. Here they are presented according to Health System Level.
**Health System Levels according to Bigdeli et al. [12]: I. Individual, household and community; II. Health service delivery; III. Health Sector; IV. Beyond the health sector (Public policies cutting across sectors; and, International and regional level).
Number of respondents by country
| Colombia | 15 |
| Dominican Republic | 12 |
| El Salvador | 11 |
| Suriname | 11 |
| Argentina | 3 |
| Bolivia | 1 |
| Brazil | 13 |
| Colombia | 3 |
| Costa Rica | 1 |
| Ecuador | 6 |
| USA | 4 |
| Guatemala | 1 |
| Mexico | 1 |
| Peru | 2 |
Source: Authors.
Respondent rankings of criteria that should be applied to define research priorities on access to medicines
| g | Relevance (magnitude of the problem; persistence of the problem; impact on health; urgency) | 0.6 | |||||
| b | Feasibility (capacity of the system to carry out the research; funding support; justification of the cost/investment; justification of time) | 1.0 | 0.8 | 0.7 | 0.7 | ||
| i | Research utilization (adequacy and usefulness of the current knowledge base (avoiding duplication); applicability of the research outcome; availability of cost-effective interventions (access); operational effectiveness) | 0.3 | 0.5 | ||||
| f | Political will/acceptability/commitment | 0.5 | 0.8 | 0.5 | 3.8 | ||
| c | Human rights issues; equity focus; ethical and moral issues | 0.7 | 0.3 | 0.6 | 3.7 | ||
| h | Responsiveness to the National Health Policy or national goals | 0.7 | 0.8 | 0.4 | 0.8 | 3.6 | |
| a | Community concern/demand; environmental health and sociopolitical effects | 0.3 | 0.3 | 0.4 | 3.0 | ||
| d | Impact on development; economic impact | 0.2 | 0.6 | 0.5 | 0.4 | 0.3 | 1.9 |
| e | Partnership building; research capacity building | 0.3 | 0.2 | 0.0 | 0.1 | 0.4 | 1.0 |
*Item codes reflect the order in which they appeared in the questionnaire. Here they are presented according to total ranking scores. Bold numbers represent the three highest scores in each setting.
Source: Authors.
Summary ranking scores for current policies, desired policies, current research, and desired research
| | | | | | |
| 1f | Clinical treatment guidelines, and essential medicines list: development; incentives for implementation; operational mechanisms; standardization (including between private and public sectors) | ||||
| 1i | Pharmacovigilance, information on adverse drug reaction, and other problems related to medicines | ||||
| 1e | Staff capacity for rational prescription and use of medicines; training curriculum | 3.0 | |||
| 1d | Impact of advertisements on medicines; incentives (or lack of, leading to private or dual practice); medicines becoming a source in financing for health services | 3.3 | 7.3 | 7.0 | |
| | | | | | |
| 2g | Policy and regulation for medicines price | ||||
| 2f | Impact of prices on access | ||||
| 2a | High out-of-pocket payment | 7.6 | 5.3 | ||
| 2l | Budget allocation to health | 6.0 | 4.6 | 4.3 | |
| 2i | Patents and intellectual property issues | 6.4 | 3.9 | 5.6 | |
| | | | | | |
| 3j | Availability of medicines (especially in public sector) | 6.3 | |||
| 3a | Geographical accessibility: physical barriers; distance to facilities; remoteness (combination of physical barriers and infrastructure weakness) | 3.9 | |||
| 3k | Quality assurance | 6.8 | |||
| 3b | Distribution systems and supply chains | 3.9 | 5.3 | ||
| 3f | Staff and technical capacity: for supply management; with managerial, interpersonal and information technology (IT) skills, with local language skills (English) | 5.1 | 1.8 | 5.3 | |
| 3c | Pharmaceutical services at local level | 4.7 | 4.3 | 2.4 | |
| | | | | | |
| 4m | Budget allocation to health | ||||
| 4e | Health insurance coverage and models | ||||
| 4f | Government budgets for medicines | 7.8 | |||
| 4h | Cost containment policies | 6.9 | 9.1 | 5.1 |
*Item codes reflect the order in which they appear in the questionnaire. Top three summary scores in each domain marked in bold numbers.
Source: Authors.
Figure 1Scatter plots between summary rankings for current and desired policies, by WHO Framework domain. Each dot represents a policy/research item.
Figure 2Scatter plots between summary rankings for current research and desired policies, by WHO Framework domain. Each dot representing a policy/research item.
Figure 3Scatter plots between summary rankings for current and desired research, by WHO Framework domain. Each dot representing a policy/research item.